Lasky Tamar, Carleton Bruce, Horton Daniel B, Kelly Lauren E, Bennett Dimitri, Czaja Angela S, Gifkins Dina, Osokogu Osemeke U, McMahon Ann W
Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Biostatistics and Epidemiology, 10903 New Hampshire Avenue, White Oak-71, Room 1253, Silver Spring, MD, 20993, USA.
MIE Resources, Baltimore, MD, USA.
Drugs Real World Outcomes. 2020 Jun;7(2):97-107. doi: 10.1007/s40801-020-00182-y.
The promise of real-world evidence (RWE) is especially relevant to pediatrics, where medicines prescribed for children are often used without evidence derived from randomized clinical trials.
The aim of this systematic review was to describe the state of RWE in pediatrics by identifying observational studies published during 2016 that used RWE to assess medication safety or effectiveness in children.
An electronic search of PubMed was combined with an extended search of references within systematic reviews and expert suggestions. Studies were included if they reported on an infant or child under 18 years with exposure to medications; assessed safety or effectiveness; specified a comparison or control group, and were published in English in 2016. Data extraction was conducted by one team member using a standardized form and reviewed by a second team member. Study quality was assessed using the GRACE checklist for rating the quality of observational studies.
After removing duplicates, 915 citations were screened and 29 studies met the eligibility criteria. Most of the eligible studies relied on primary data collection or chart review at a single institution and did not use the growing number of administrative or electronic health record databases available. One-quarter of the studies did not use well-established statistical methods to control for confounders. No single disease group or medication predominated, and age groups ranged from infants to adolescents.
A small body of observational studies published in 2016 were categorized by the study team as using real-world data to assess medication safety or effectiveness in children. Studies varied in age groups, diseases or conditions, and methods, and may not have fully met the FDA definition of RWE. Our review indicates that the use of RWE is not fully developed in pediatrics, and suggests an opportunity to further develop capabilities and more fully leverage administrative and electronic health record databases to study medication safety and effectiveness in children. Our systematic review appears generalizable to pediatrics broadly, and documents that the high level of activity in RWE in general has had less of an impact on pediatrics.
真实世界证据(RWE)的前景与儿科学尤其相关,因为给儿童开的药常常在没有来自随机临床试验证据的情况下使用。
本系统评价的目的是通过识别2016年发表的使用RWE评估儿童用药安全性或有效性的观察性研究,来描述儿科学中RWE的现状。
对PubMed进行电子检索,并结合对系统评价中的参考文献进行扩展检索以及专家建议。如果研究报告了18岁以下婴儿或儿童接触药物的情况;评估了安全性或有效性;指定了比较组或对照组,并且于2016年以英文发表,则纳入研究。由一名团队成员使用标准化表格进行数据提取,并由另一名团队成员进行审核。使用GRACE清单评估观察性研究的质量来评估研究质量。
去除重复项后,筛选了915篇引文,29项研究符合纳入标准。大多数符合条件的研究依赖于单一机构的原始数据收集或病历审查,并未使用越来越多可用的行政或电子健康记录数据库。四分之一的研究未使用成熟的统计方法来控制混杂因素。没有单一的疾病组或药物占主导地位,年龄组涵盖婴儿至青少年。
研究团队将2016年发表的一小部分观察性研究归类为使用真实世界数据评估儿童用药安全性或有效性。这些研究在年龄组、疾病或病症以及方法方面各不相同,可能未完全符合美国食品药品监督管理局(FDA)对RWE的定义。我们的评价表明,RWE在儿科学中的应用尚未充分发展,并提示有机会进一步发展能力,更充分地利用行政和电子健康记录数据库来研究儿童用药的安全性和有效性。我们的系统评价似乎可广泛推广至儿科学领域,并证明RWE总体上的高度活跃对儿科学的影响较小。